Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR8068 + adebrelimab + irinotecan liposome in advanced metastatic esophageal squamous cell carcinoma after failure of first-line PD-1/PD-L1 therapy
ChiCTR2400091795Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- May 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CS1002, adebrelimab and irinotecan liposome in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Objective response rate. Planned start May 2024; status: not yet recruiting.
02
Drugs
CS1002adebrelimabirinotecan liposome
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2400091795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091795.